AR066660A1 - Prevencion y tratamiento de condiciones del ojo asociadas con su complemento - Google Patents

Prevencion y tratamiento de condiciones del ojo asociadas con su complemento

Info

Publication number
AR066660A1
AR066660A1 ARP080102150A ARP080102150A AR066660A1 AR 066660 A1 AR066660 A1 AR 066660A1 AR P080102150 A ARP080102150 A AR P080102150A AR P080102150 A ARP080102150 A AR P080102150A AR 066660 A1 AR066660 A1 AR 066660A1
Authority
AR
Argentina
Prior art keywords
factor
antibody
use according
complement
prevention
Prior art date
Application number
ARP080102150A
Other languages
English (en)
Spanish (es)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39638868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR066660(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR066660A1 publication Critical patent/AR066660A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
ARP080102150A 2007-05-23 2008-05-21 Prevencion y tratamiento de condiciones del ojo asociadas con su complemento AR066660A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93979107P 2007-05-23 2007-05-23

Publications (1)

Publication Number Publication Date
AR066660A1 true AR066660A1 (es) 2009-09-02

Family

ID=39638868

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102150A AR066660A1 (es) 2007-05-23 2008-05-21 Prevencion y tratamiento de condiciones del ojo asociadas con su complemento

Country Status (28)

Country Link
US (6) US8007791B2 (OSRAM)
EP (1) EP2152755B1 (OSRAM)
JP (4) JP5416695B2 (OSRAM)
KR (1) KR101540126B1 (OSRAM)
CN (3) CN104367999A (OSRAM)
AR (1) AR066660A1 (OSRAM)
AU (1) AU2008256835B2 (OSRAM)
BR (1) BRPI0811142A8 (OSRAM)
CA (1) CA2683498A1 (OSRAM)
CL (1) CL2008001498A1 (OSRAM)
CY (1) CY1116062T1 (OSRAM)
DK (1) DK2152755T3 (OSRAM)
ES (1) ES2533242T3 (OSRAM)
HK (1) HK1207327A1 (OSRAM)
HR (1) HRP20150281T1 (OSRAM)
IL (2) IL201476A (OSRAM)
MX (1) MX2009012422A (OSRAM)
PE (1) PE20090294A1 (OSRAM)
PH (1) PH12013500992B1 (OSRAM)
PL (1) PL2152755T3 (OSRAM)
PT (1) PT2152755E (OSRAM)
RS (1) RS53901B1 (OSRAM)
RU (2) RU2522976C2 (OSRAM)
SG (1) SG10201401404RA (OSRAM)
SI (1) SI2152755T1 (OSRAM)
TW (2) TW201417829A (OSRAM)
WO (1) WO2008147883A1 (OSRAM)
ZA (1) ZA200907028B (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2026073B1 (en) * 2000-04-29 2016-03-30 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
ES2551202T5 (es) * 2005-11-04 2018-11-30 Genentech, Inc. Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
CN106084054A (zh) 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
MX2011002367A (es) * 2008-09-02 2011-04-04 Novartis Ag Inhibidores de cinasa biciclicos.
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CA3045436C (en) 2009-01-29 2025-10-07 Forsight Vision4 Inc Posterior segment drug delivery
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
HUE057267T2 (hu) * 2010-08-05 2022-05-28 Forsight Vision4 Inc Berendezés szem kezelésére
PL2635704T3 (pl) * 2010-11-01 2017-09-29 F.Hoffmann-La Roche Ag Przewidywanie progresji do zaawansowanego zwyrodnienia plamki żółtej związanego z wiekiem z zastosowaniem wskaźnika poligenicznego
WO2012093101A1 (en) 2011-01-04 2012-07-12 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
JP6273274B2 (ja) 2012-06-28 2018-01-31 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
JP6155332B2 (ja) 2012-06-28 2017-06-28 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
WO2014002052A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
ES2712190T3 (es) 2012-06-28 2019-05-09 Novartis Ag Moduladores de la vía del complemento y sus usos
JP6209605B2 (ja) 2012-06-28 2017-10-04 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
EA201590200A1 (ru) 2012-07-12 2015-08-31 Новартис Аг Модуляторы пути активации комплемента и их применение
SG11201500489YA (en) 2012-07-25 2015-02-27 Kolltan Pharmaceuticals Inc Anti-kit antibodies and uses thereof
WO2014120555A1 (en) 2013-01-31 2014-08-07 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of use thereof
ES2972168T3 (es) 2013-03-28 2024-06-11 Forsight Vision4 Inc Implante oftálmico para administración de sustancias terapéuticas
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
EP3054965B1 (en) * 2013-10-07 2021-04-14 Massachusetts Eye & Ear Infirmary Anti-factor d antibody for use in preventing or reducing retinal detachment
AU2014339890A1 (en) * 2013-10-25 2016-06-02 Children's Medical Center Corporation Methods of treating or preventing vascular diseases of the retina
SG11201608868PA (en) * 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
CN106659782B (zh) 2014-05-23 2021-11-09 塞尔德克斯医疗公司 一种用于嗜酸性粒细胞或肥大细胞相关病症治疗的抗体
SI3352776T1 (sl) * 2015-09-23 2025-08-29 Sangamo Therapeutics, Inc. Represorji Htt in njihove uporabe
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
EP3368682B1 (en) 2015-10-30 2019-12-11 H. Hoffnabb-La Roche Ag Methods of measuring factor d activity and potency of factor d inhibitors
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
SI3368578T1 (sl) 2015-10-30 2021-08-31 F. Hoffmann-La Roche Ag Protitelesa proti HtrA1 in postopki uporabe
HUE056019T2 (hu) * 2015-12-23 2022-01-28 eleva GmbH Polipeptidek komplement aktiváció gátlására
CN108934169A (zh) * 2016-01-20 2018-12-04 维特里萨医疗公司 用于抑制因子d的组合物和方法
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
CA3053155A1 (en) * 2017-02-10 2018-08-16 The Trustees Of The University Of Pennsylvania Anti-factor d antibodies and uses thereof
CN109632924B (zh) * 2018-12-17 2022-02-08 上海市第一人民医院 人黄斑新生血管性疾病的血浆脂质标记物及其应用
WO2021009777A2 (en) * 2019-07-18 2021-01-21 Pandorum Technologies Private Limited Methods of stem cell culture for obtaining products, and implementations thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620915B2 (en) * 1993-12-23 2003-09-16 Icos Corporation Monoclonal antibodies specific for integrin α-d subunit
WO2002000690A2 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO1999040100A1 (en) * 1998-02-09 1999-08-12 Human Genome Sciences, Inc. 45 human secreted proteins
US20050197285A1 (en) * 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) * 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US7419663B2 (en) * 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US7282565B2 (en) * 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
ES2305608T3 (es) 1997-11-21 2008-11-01 Genentech, Inc. Antigenos tipo a-33 y sus utilizaciones farmacologicas.
US8007798B2 (en) * 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
DE69939813D1 (de) * 1998-02-20 2008-12-11 Tanox Inc Inhibitoren der komplement-aktivierung
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
DK1490386T3 (da) 1998-03-10 2008-12-15 Genentech Inc Nyt polypeptid og nukleinsyrer kodende for dette
CA2340794A1 (en) 1998-08-27 2000-03-09 Incyte Pharmaceuticals, Inc. Protein transport-associated molecules
CA2348757A1 (en) 1998-12-16 2000-06-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE69930872T8 (de) * 1998-12-21 2007-05-03 Ludwig Institute For Cancer Research Antikörper gegen verkürzten vegf-d und deren verwendungen
JP3993746B2 (ja) 1998-12-22 2007-10-17 ジェネンテック・インコーポレーテッド 腫瘍性細胞成長阻害のための組成物及び方法
KR20010103046A (ko) 1999-03-08 2001-11-17 제넨테크, 인크. 면역 관련 질환 치료용 조성물 및 치료 방법
CN1637019A (zh) 1999-03-11 2005-07-13 Rmf迪克塔吉恩有限公司 血管粘着分子及其功能的调节
US6642353B1 (en) * 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
AU2883900A (en) 1999-07-07 2001-01-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
UA72943C2 (uk) 1999-11-02 2005-05-16 Ульяновскій Государствєнний Тєхніческій Унівєрсітєт Спосіб очищення рідини від феромагнітних частинок (варіанти) і пристрій для його здійснення (варіанти)
AU1604401A (en) 1999-11-19 2001-05-30 Human Genome Sciences, Inc. 18 human secreted proteins
EP1686134A3 (en) 1999-12-01 2006-08-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20040152105A1 (en) * 2002-09-06 2004-08-05 Cytos Biotechnology Ag. Immune modulatory compounds and methods
RU2232991C1 (ru) * 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
ES2551202T5 (es) * 2005-11-04 2018-11-30 Genentech, Inc. Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
CN106084054A (zh) * 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
JP4349447B2 (ja) 2007-07-19 2009-10-21 トヨタ自動車株式会社 インバータ制御装置および車両

Also Published As

Publication number Publication date
KR101540126B1 (ko) 2015-07-28
JP2017197577A (ja) 2017-11-02
HK1207327A1 (en) 2016-01-29
CN104367999A (zh) 2015-02-25
US8007791B2 (en) 2011-08-30
AU2008256835B2 (en) 2013-08-01
BRPI0811142A2 (pt) 2014-12-23
TW200904471A (en) 2009-02-01
JP5416695B2 (ja) 2014-02-12
IL201476A (en) 2016-11-30
DK2152755T3 (en) 2015-03-02
IL248552A0 (en) 2016-12-29
TWI419704B (zh) 2013-12-21
CN101754980B (zh) 2014-10-29
RU2522976C2 (ru) 2014-07-20
CN107096029A (zh) 2017-08-29
JP2016145205A (ja) 2016-08-12
HRP20150281T1 (hr) 2015-04-10
RU2009147744A (ru) 2011-06-27
KR20100033973A (ko) 2010-03-31
MX2009012422A (es) 2009-12-04
US20130052685A1 (en) 2013-02-28
TW201417829A (zh) 2014-05-16
US8268310B2 (en) 2012-09-18
CL2008001498A1 (es) 2009-06-12
US20160272726A1 (en) 2016-09-22
CN107096029B (zh) 2021-02-26
ZA200907028B (en) 2010-12-29
JP2014087346A (ja) 2014-05-15
PH12013500992B1 (en) 2018-12-14
SI2152755T1 (sl) 2015-05-29
PT2152755E (pt) 2015-04-01
SG10201401404RA (en) 2014-08-28
CA2683498A1 (en) 2008-12-04
EP2152755A1 (en) 2010-02-17
EP2152755B1 (en) 2014-12-31
RS53901B1 (sr) 2015-08-31
WO2008147883A1 (en) 2008-12-04
PH12013500992A1 (en) 2016-01-25
JP2010528047A (ja) 2010-08-19
CY1116062T1 (el) 2017-02-08
PE20090294A1 (es) 2009-03-27
US20110282034A1 (en) 2011-11-17
CN101754980A (zh) 2010-06-23
ES2533242T3 (es) 2015-04-08
PL2152755T3 (pl) 2015-06-30
IL201476A0 (en) 2010-05-31
AU2008256835A1 (en) 2008-12-04
US20180079826A1 (en) 2018-03-22
BRPI0811142A8 (pt) 2018-12-18
RU2014113046A (ru) 2015-10-10
WO2008147883A8 (en) 2013-05-23
US8497094B2 (en) 2013-07-30
US20090181017A1 (en) 2009-07-16
HK1139161A1 (en) 2010-09-10
US20130302333A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
AR066660A1 (es) Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
JP2010528047A5 (OSRAM)
PE20191758A1 (es) Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
JP2018534933A5 (OSRAM)
FI3487882T3 (fi) Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja
ECSP16060104A (es) Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este
ME03755B (me) Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa
JP2017536341A5 (OSRAM)
AR099698A1 (es) Anticuerpos contra el c5 que tienen farmacocinética mejorada
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
JP2016531915A5 (OSRAM)
JP2016538318A5 (OSRAM)
JP2015503909A5 (OSRAM)
CL2013003373A1 (es) Proteina de union al antigeno de maduración de linfocitos b (bcma); composicion farmacéutica que comprende la proteína; uso para preparar un medicamento util para tratar mieloma multiple o (mm) leucemia linfocitica cronica (cll).
WO2008154251A4 (en) C3b antibodies and methods for the prevention and treatment of complement- associated disorders
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
RU2011144312A (ru) БИСПЕЦИФИЧЕСКИЕ АНТИ-ErbB-3/АНТИ-С-МЕТ АНТИТЕЛА
RU2017120358A (ru) Анти-il-1-бета антитела и способы их применения
RU2015144105A (ru) Антитела к гепсидину и их применения
RU2016137110A (ru) Антитела к компоненту комплемента с5
WO2016090024A4 (en) Combination therapy for treatment of cancer
RU2016137256A (ru) АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb
RU2017104642A (ru) Новое антитело против tie-2 человека
RU2018100824A (ru) Антитела, которые связываются с сортилином и подавляют связывание програнулина

Legal Events

Date Code Title Description
FB Suspension of granting procedure